Wolfe Research Upgrades Intellia Therapeutics (NASDAQ:NTLA) to "Outperform"

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) was upgraded by investment analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating in a research report issued on Monday, Marketbeat.com reports. The brokerage presently has a $21.00 price target on the stock. Wolfe Research's price target points to a potential upside of 159.10% from the stock's current price.

Other equities research analysts also recently issued reports about the stock. StockNews.com upgraded shares of Intellia Therapeutics to a "sell" rating in a research note on Monday, March 3rd. HC Wainwright assumed coverage on Intellia Therapeutics in a research note on Wednesday, March 5th. They set a "buy" rating and a $30.00 target price for the company. Wells Fargo & Company dropped their price target on Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Chardan Capital cut their price target on Intellia Therapeutics from $91.00 to $68.00 and set a "buy" rating for the company in a report on Friday, February 28th. Finally, Oppenheimer decreased their price objective on shares of Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating on the stock in a report on Monday, January 13th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Intellia Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $36.68.

Intellia Therapeutics Stock Performance

NTLA traded down $0.21 during trading on Monday, reaching $8.11. 2,562,048 shares of the stock were exchanged, compared to its average volume of 2,375,855. The stock has a market cap of $839.01 million, a P/E ratio of -1.49 and a beta of 2.23. The stock's 50 day moving average price is $8.78 and its two-hundred day moving average price is $11.99. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.18.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in NTLA. GF Fund Management CO. LTD. bought a new position in Intellia Therapeutics in the 4th quarter valued at approximately $25,000. Sterling Capital Management LLC boosted its holdings in shares of Intellia Therapeutics by 866.2% during the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock valued at $37,000 after acquiring an additional 2,867 shares in the last quarter. Whipplewood Advisors LLC bought a new stake in shares of Intellia Therapeutics during the fourth quarter worth about $40,000. Resona Asset Management Co. Ltd. bought a new position in Intellia Therapeutics in the 4th quarter valued at approximately $43,000. Finally, Jones Financial Companies Lllp increased its position in Intellia Therapeutics by 140.9% in the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company's stock valued at $45,000 after acquiring an additional 2,280 shares during the period. Institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.